

Marc L Berger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9251039/publications.pdf>

Version: 2024-02-01

58
papers

4,475
citations

186265
28
h-index

138484
58
g-index

59
all docs

59
docs citations

59
times ranked

4940
citing authors

#	ARTICLE	IF	CITATIONS
1	Toward Facilitated Self-Service in Health Care. <i>New England Journal of Medicine</i> , 2019, 380, 1891-1893.	27.0	9
2	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. <i>Value in Health</i> , 2019, 22, 13-20.	0.3	76
3	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ESPE Special Task Force on Real-World Evidence in Health Care Decision Making. <i>Value in Health</i> , 2017, 20, 1003-1008.	0.3	243
4	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , 2017, 20, 1009-1022.	0.3	70
5	Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies. <i>Medical Care</i> , 2017, 55, 244-251.	2.4	18
6	Big Data: transforming drug development and health policy decision making. <i>Health Services and Outcomes Research Methodology</i> , 2016, 16, 92-102.	1.8	20
7	Opportunities and challenges in leveraging electronic health record data in oncology. <i>Future Oncology</i> , 2016, 12, 1261-1274.	2.4	82
8	Optimizing the Leveraging of Real-World Data to Improve the Development and Use of Medicines. <i>Value in Health</i> , 2015, 18, 127-130.	0.3	45
9	Big data, advanced analytics and the future of comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 167-176.	1.4	39
10	A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. <i>Value in Health</i> , 2014, 17, 143-156.	0.3	96
11	Can the pharmaceutical industry embrace comparative effectiveness research? A view from inside. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 565-568.	1.4	3
12	The role of private industry in pragmatic comparative effectiveness trials. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 147-156.	1.4	13
13	Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2012, 15, 217-230.	0.3	151
14	Raising the Bar of Efficacy for Drug Approval Requires an Understanding of Patient Diversity. <i>Journal of Clinical Oncology</i> , 2010, 28, e343-e344.	1.6	6
15	Comparative Effectiveness Research. <i>Pharmacoeconomics</i> , 2010, 28, 915-922.	3.3	13
16	GRACE principles: recognizing high-quality observational studies of comparative effectiveness. <i>American Journal of Managed Care</i> , 2010, 16, 467-71.	1.1	103
17	Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I. <i>Value in Health</i> , 2009, 12, 1044-1052.	0.3	305
18	Valuing reductions in on-the-job illness: "presenteeism" from managerial and economic perspectives. <i>Health Economics (United Kingdom)</i> , 2008, 17, 469-485.	1.7	136

#	ARTICLE	IF	CITATIONS
19	Getting Real Performance Out of Payâ€forâ€Performance. Milbank Quarterly, 2008, 86, 435-457.	4.4	25
20	Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. American Journal of Health-System Pharmacy, 2007, 64, 637-643.	1.0	30
21	The Decision to Conduct a Head-to-Head Comparative Trial: A Game-Theoretic Analysis. Medical Decision Making, 2007, 27, 364-379.	2.4	6
22	Measuring the effects of work loss on productivity with team production. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	147
23	Cost-Effectiveness Analysis. Medical Care, 2005, 43, II-49.	2.4	13
24	Comparative Effectiveness: Asking The Right Questions, Choosing The Right Method. Health Affairs, 2005, 24, 128-132.	5.2	49
25	How to Present the Business Case for Healthcare Quality to Employers. Applied Health Economics and Health Policy, 2005, 4, 209-218.	2.1	28
26	Evidence Synthesis and Evidence-Based Decision Making: Related But Distinct Processes. Medical Decision Making, 2005, 25, 487-489.	2.4	15
27	Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis. Clinical Therapeutics, 2005, 27, 960-969.	2.5	27
28	Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. American Journal of Managed Care, 2005, 11, 621-8.	1.1	47
29	Osteoporosis and Fracture Risk in Women of Different Ethnic Groups. Journal of Bone and Mineral Research, 2004, 20, 185-194.	2.8	459
30	Bone Mineral Density Thresholds for Pharmacologic Intervention to Prevent Fractures. Obstetrical and Gynecological Survey, 2004, 59, 769-771.	0.4	2
31	A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organization. Preventing Chronic Disease, 2004, 1, A05.	3.4	17
32	Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause, 2003, 10, 412-419.	2.0	67
33	Do NSAIDs cause dyspepsia? a meta-analysis evaluating alternative dyspepsia definitions. American Journal of Gastroenterology, 2002, 97, 1951-1958.	0.4	57
34	A general model of the impact of absenteeism on employers and employees. Health Economics (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	127
35	Treatment of Migraine With Rizatriptan: When to Take the Medication. Headache, 2002, 42, 16-20.	3.9	43
36	Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment. Journal of Bone and Mineral Research, 2002, 17, 2222-2230.	2.8	284

#	ARTICLE	IF	CITATIONS
37	A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. <i>Journal of Rheumatology</i> , 2002, 29, 804-12.	2.0	166
38	Growth in use of lipid-lowering therapies: are we targeting the right patients?. <i>American Journal of Managed Care</i> , 2002, 8, 862-7.	1.1	10
39	Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices. <i>American Journal of Managed Care</i> , 2002, 8, 937-46.	1.1	5
40	Disease Management: An Intermediate Step Toward Integrated and Coordinated Patient Care. <i>Disease Management: DM</i> , 2001, 4, 173-178.	1.0	2
41	Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2815.	7.4	1,006
42	The Value of Disease Management. <i>Disease Management and Health Outcomes</i> , 2000, 8, 181-184.	0.4	4
43	A Population-Based Approach to Asthma Disease Management. <i>Disease Management and Health Outcomes</i> , 2000, 7, 179-186.	0.4	12
44	Efficient Patient Identification Strategies for Women with Osteoporosis. <i>Journal of Clinical Densitometry</i> , 1999, 2, 223-231.	1.2	14
45	Effectiveness of antihyperlipidemic drug management in clinical practice. <i>Clinical Therapeutics</i> , 1999, 21, 1973-1987.	2.5	12
46	Quality-of-life questionnaire for patients taking antihypertensive medication. <i>Clinical Therapeutics</i> , 1999, 21, 1771-1787.	2.5	12
47	The Once and Future Application of Cost-Effectiveness Analysis. <i>The Joint Commission Journal on Quality Improvement</i> , 1999, 25, 455-461.	1.5	13
48	A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996, 1, 101-106.	2.0	12
49	Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. <i>American Journal of Cardiology</i> , 1996, 77, 475-479.	1.6	19
50	Novel Oral Medication Delivery System for Famotidine. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 362-367.	2.0	9
51	Anoxic hepatocyte injury: Role of reversible changes in elemental content and distribution. <i>Hepatology</i> , 1989, 9, 219-228.	7.3	30
52	Toxicity of methylating agents in isolated hepatocytes. <i>Biochemical Pharmacology</i> , 1988, 37, 3183-3188.	4.4	31
53	Studies on calcium transport during carbon tetrachloride mediated hepatotoxicity in mice. <i>Biochemical Pharmacology</i> , 1988, 37, 4584-4586.	4.4	4
54	Intervention in free radical mediated hepatotoxicity and lipid peroxidation by indole-3-carbinol. <i>Biochemical Pharmacology</i> , 1988, 37, 333-338.	4.4	68

#	ARTICLE	IF	CITATIONS
55	Rapid halogenated hydrocarbon toxicity in isolated hepatocytes is mediated by direct solvent effects. <i>Toxicology</i> , 1987, 45, 319-330.	4.2	16
56	Carbon tetrachloride-induced morphologic alterations in isolated rat hepatocytes. <i>Experimental and Molecular Pathology</i> , 1987, 46, 245-257.	2.1	23
57	CCl ₄ induced toxicity in isolated hepatocytes: The importance of direct solvent injury. <i>Hepatology</i> , 1986, 6, 36-45.	7.3	114
58	Scurvy as an Initial Manifestation of Whipple's Disease. <i>Annals of Internal Medicine</i> , 1984, 101, 58.	3.9	22